Dr. Reddys Laboratories is currently trading at Rs. 3841.35, up by 96.85 points or 2.59% from its previous closing of Rs. 3744.50 on the BSE.
The scrip opened at Rs. 3775.00 and has touched a high and low of Rs. 3893.95 and Rs. 3775.00 respectively. So far 1379 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 3,893.95 on 15-Apr-2020 and a 52 week low of Rs. 2352.00 on 14-Aug-2019.
Last one week high and low of the scrip stood at Rs. 3893.95 and Rs. 3480.50 respectively. The current market cap of the company is Rs. 62223.14 crore.
The promoters holding in the company stood at 26.76%, while Institutions and Non-Institutions held 45.14% and 13.80% respectively.
Dr. Reddy's Laboratories has launched authorized generic version of NitroDur (nitroglycerin) Transdermal Infusion System. The combined market for all Nitrogylcerin Transdermal Patch products had US sales of around $14.7 million MAT for the most recent twelve months ending in January 2020 according to IQVIA Health.
The company’s Nitroglycerin Transdermal Infusion System is available in four dosage strengths: 0.1 mg/hr, 0.2 mg/hr, 0.4 mg/hr, and 0.6 mg/hr, each in a box of 30 count. NitroDur is a trademark of USpharma.
Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1847.30 |
| Dr. Reddys Lab | 1293.25 |
| Cipla | 1347.70 |
| Zydus Lifesciences | 938.90 |
| Lupin | 2377.90 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: